AB0320 Matrix Metalloproteinase-3 Levels in Rheumatoid Arthritis and its Relationship with Other Diseases

Background Rheumatoid Arthritis (RA) and ankylosing spondylitis (AS) are chronic inflammatory diseases that often occur in the society and affect the life quality in a negative way. Since they cause serious morbidity and mortality, early diagnosis and treatment are essential in these diseases. The studies about the diagnostic importance of antibodies (anti MCV) appearing against sitrulin vimentin in RA and AS have recently attracted much attention. Objectives In this study, anti MCV levels and its relationship with other disease parameters were searched in the diagnosis of RA and AS. Methods Three groups including 30 RA, 30 AS and 30 healthy controls were formed. In all the groups, anti MCV levels were measured by ELISA method. In addition, the patients9 ESH, CRP, anti CCP, RF levels were examined. HAQ and NHP scoring were used to measure disability. While, DAS28 was calculated to determine the activation in the patients with RA, in the patients with AS, BASDAI and BASFI were calculated. The relationship of these parameters with anti MCV levels was examined. Results While anti MCV levels are determined to be high and statistically significant in Rheumatoid Arthritis and AS group in comparison with healthy control group, any significant difference in anti MCV levels was not determined between RA and AS. Anti MCV levels were positive in 19 patients out of 30 with RA, in 16 patients out of 30 with AS and in 10 patients out of 30 in healthy control group. According to these results, the sensitivity of anti MCV was found to be 63.3% and the specificity of anti MCV was 66.6% in RA, the sensitivity of anti MCV was 53.3% and the specificity of anti MCV was 66.6% in AS. The relationship of anti MCV levels with ESH, CRP, anti CCP, RF levels and activation parameters such as DAS28, BASDAI and BASFI was not determined. Conclusions As a result, anti MCV is thought to be used as a diagnostic marker in the diagnosis of Ra and AS. However, large-scale studies about disease activation and use in follow-up after treatment are needed. Disclosure of Interest None declared